91817-66-2Relevant academic research and scientific papers
As opioid receptor antagonists or inverse agonists of the novel compounds
-
Paragraph 0331; 0332, (2016/10/08)
Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS
-
, (2011/06/19)
Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
N- INDEN- 2 -YL- ISOPROPYLSULFONAMIDES AS AMPA RECEPTOR POTENTIATORS
-
Page/Page column 25-26, (2010/07/10)
A compound of formula (I) and salts thereof are provided: Wherein n and R1 are defined in the specification. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or
METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS
-
, (2010/05/13)
A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.
NOVEL HETEROCYCLE COMPOUNDS
-
Page/Page column 45-46, (2009/04/24)
The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.
